Recombinant TCF7L2 Antibody: Selection & Application Guide

Recombinant TCF7L2 Antibody is a highly specific research tool designed to detect and study TCF7L2, a critical transcription factor in the Wnt/β-catenin signaling pathway with well-established links to type 2 diabetes, colorectal cancer, and stem cell regulation.

Product SKU

Ab379166

Antibody Type

Recombinant monoclonal antibody

Target Protein

TCF7L2 (also known as TCF4)

Biological Relevance

Key transcription factor in Wnt/β-catenin signaling; associated with type 2 diabetes susceptibility and colorectal cancer

Recommended Applications

Western blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)

Storage Recommendation

Store at -20 °C; avoid repeated freeze-thaw cycles

TCF7L2 Biology and Research Significance

TCF7L2 (Transcription Factor 7-Like 2), historically referred to as TCF4, is a high-mobility group (HMG) box-containing transcription factor and a pivotal effector of the canonical Wnt/β-catenin signaling pathway. Upon Wnt ligand activation, cytoplasmic β-catenin translocates to the nucleus where it forms a transcriptional complex with TCF7L2, driving expression of target genes involved in cell proliferation, differentiation, and survival.

TCF7L2 has attracted intense research interest across multiple disease areas. Genome-wide association studies (GWAS) have reproducibly identified variants in the TCF7L2 gene locus as among the strongest common genetic risk factors for type 2 diabetes mellitus (T2DM), influencing pancreatic β-cell function and insulin secretion. In oncology, TCF7L2 is frequently dysregulated in colorectal cancer, hepatocellular carcinoma, and other malignancies, making it a relevant biomarker and potential therapeutic target. Its role in intestinal stem cell maintenance and epithelial homeostasis further underscores its broad biological significance.

Reliable detection of TCF7L2 protein expression, isoform distribution, and post-translational modifications requires well-validated antibodies. The recombinant format of Ab379166 offers enhanced batch-to-batch consistency compared to traditional hybridoma-derived antibodies, a critical advantage for longitudinal studies and multi-site collaborations.

Experimental Protocols and Recommended Applications

Western Blot (WB): For WB applications, lyse cells or tissue in RIPA buffer supplemented with protease and phosphatase inhibitors. Resolve 20–50 µg of total protein on a 10% SDS-PAGE gel and transfer to PVDF membrane. Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature. Incubate with Recombinant TCF7L2 Antibody (Ab379166) overnight at 4 °C at the manufacturer's recommended dilution. Wash three times with TBST, then incubate with appropriate HRP-conjugated secondary antibody. Detect by enhanced chemiluminescence (ECL). TCF7L2 is expected to appear as a band in the range of approximately 58–80 kDa depending on isoform and post-translational modifications; verify with positive control lysate.

Immunohistochemistry (IHC): Fix tissue sections in 10% neutral buffered formalin and embed in paraffin (FFPE). Perform antigen retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) as appropriate. Block endogenous peroxidase and non-specific binding. Apply the primary antibody at the recommended dilution and incubate overnight at 4 °C in a humidified chamber. Use a validated polymer-based detection system and DAB chromogen. Counterstain with hematoxylin. Nuclear staining pattern is expected for TCF7L2.

Immunofluorescence (IF): Fix cells with 4% paraformaldehyde, permeabilize with 0.1–0.2% Triton X-100, and block with 5% normal serum. Incubate with Ab379166 at recommended dilution for 1 hour at room temperature or overnight at 4 °C. Detect with a fluorophore-conjugated secondary antibody and counterstain nuclei with DAPI. TCF7L2 localizes predominantly to the nucleus.

Note: Exact dilutions, incubation times, and buffer compositions should be optimized empirically for each laboratory's specific samples and equipment. Always refer to the product datasheet for the most current recommendations.

Storage, Handling, and Quality Considerations

Storage: Recombinant TCF7L2 Antibody (Ab379166) should be stored at -20 °C upon receipt. For antibodies supplied in glycerol-containing buffer, storage at -20 °C is typically appropriate for long-term stability. Aliquot the antibody into single-use volumes before freezing to minimize the number of freeze-thaw cycles, which can degrade antibody performance over time.

Handling: Thaw on ice prior to use. Brief centrifugation (e.g., 5,000 × g for 30 seconds) after thawing is recommended to collect any condensation from the tube cap. Avoid prolonged exposure to room temperature. Do not vortex vigorously, as mechanical shear can denature antibody molecules.

Recombinant Advantage: Unlike hybridoma-derived monoclonal antibodies, recombinant antibodies are produced from defined genetic sequences in expression systems, ensuring high lot-to-lot consistency, reduced risk of mycoplasma contamination, and suitability for animal-free research programs. These properties make Ab379166 particularly well-suited for regulated research environments and reproducibility-focused studies.

Expiry and QC: Always check the expiry date on the vial label. Perform a positive control experiment with each new lot to confirm expected performance before committing large sample sets.

Troubleshooting Common Issues

No signal or weak signal: Verify that the target protein is expressed in your cell or tissue model. Confirm antigen retrieval conditions for IHC. Check that secondary antibody species specificity matches the host species of Ab379166. Increase primary antibody concentration or extend incubation time incrementally. Ensure the detection reagent and ECL substrate are not expired.

High background or non-specific bands: Optimize blocking conditions — try 5% BSA instead of milk if phosphorylation-specific detection is involved, as milk contains casein (a phosphoprotein). Increase washing stringency (number and duration of washes). Titrate the primary antibody downward. For IHC, confirm that endogenous peroxidase and biotin have been adequately blocked.

Multiple bands on Western blot: TCF7L2 is alternatively spliced and generates multiple isoforms; multiple bands can be biologically expected. Cross-reference band pattern with published literature and positive control lysates. Ensure complete denaturation of samples by heating in loading buffer at 95–100 °C for 5–10 minutes.

Inconsistent results between experiments: Standardize lysis and sample preparation protocols. Use the same lot of antibody within a study where possible. Include internal loading controls (e.g., β-actin, GAPDH) and positive control samples in every experiment to enable normalization and cross-experiment comparison.

Frequently asked questions

What is TCF7L2 and why is it an important research target?

TCF7L2 (Transcription Factor 7-Like 2) is an HMG-box transcription factor and a central mediator of the Wnt/β-catenin signaling pathway. It regulates genes involved in cell proliferation, differentiation, and metabolic function. Variants in the TCF7L2 locus are the most robustly replicated common genetic risk factors for type 2 diabetes, and TCF7L2 is also implicated in colorectal and other cancers, making it a high-priority target across metabolic disease and oncology research.

What are the advantages of using a recombinant antibody over a conventional monoclonal antibody for TCF7L2 detection?

Recombinant antibodies are produced from defined DNA sequences in controlled expression systems, ensuring superior lot-to-lot consistency compared to hybridoma-derived antibodies, which can drift over cell passages. Recombinant production also eliminates risks associated with animal immunization batches, reduces potential mycoplasma contamination, and supports animal-free research initiatives. These features translate to more reproducible experimental results across time and between laboratories.

Which cell lines or tissue types are recommended as positive controls for TCF7L2 Western blot?

Cell lines with known high TCF7L2 expression, such as colorectal cancer cell lines (e.g., HCT116, SW480, LS174T) and certain pancreatic cell lines, are commonly used as positive controls in the literature. Human colon tissue is also frequently cited as a positive control tissue for IHC. Researchers should verify expression in their specific model system and consult the product datasheet for Aladdin's tested positive controls for Ab379166.

How should I handle and store Ab379166 to maintain antibody performance?

Store Ab379166 at -20 °C immediately upon receipt. Aliquot into single-use volumes before freezing to avoid repeated freeze-thaw cycles, which degrade antibody activity. Thaw on ice before use, briefly centrifuge to collect condensation, and keep on ice during the experiment. Do not vortex vigorously. Always check the expiry date before use.

Can Ab379166 be used for chromatin immunoprecipitation (ChIP) assays?

The product datasheet for Ab379166 should be consulted to confirm validated applications. ChIP compatibility depends on whether the antibody epitope is accessible in native chromatin context and requires specific validation. If ChIP is not listed as a validated application, contact Aladdin Scientific's technical support team for guidance before proceeding.

References

1. Grant SF, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nature Genetics, 2006.
2. Korinek V, et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nature Genetics, 1998.
3. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell, 2012.
4. Aladdin Scientific. Ab379166 Recombinant TCF7L2 Antibody product datasheet. Aladdin Scientific, current version.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.